School of Pharmacy, Gyeongsang National University, Jinju, South Korea; Institute of Pharmacy, Gyeongsang National University, Jinju, South Korea.
Health Insurance Research Institute, National Health Insurance Service, Wonju, South Korea.
Health Policy. 2020 Oct;124(10):1108-1114. doi: 10.1016/j.healthpol.2020.06.010. Epub 2020 Jun 26.
This study explored if Koreans consider the type of disease, rarity, and availability of alternative treatments as priority criteria in limited healthcare resource allocation.
A web-based survey was conducted with a representative sample of 3,482 Korean adults. Participants were divided into six cohorts, differing in terms of the disease being compared and the cost and benefits of the treatments. Each cohort was asked two questions: 1) How to allocate a fixed budget into each of the two groups (cancer vs non-cancer, rare vs common, no other treatments available vs several treatments available), all else being equal; 2) allocation choices when conditions of two groups differed. The McNemar test was used to assess changes in responses between the two questions.
Under the control condition, the majority chose to treat an even number of patients with cancer and non-cancer diseases, and preferred to treat common diseases and those with no alternative treatments. However, when the treatment effects or costs of two comparison groups changed, choice shifted toward more effective or less costly treatment.
While Koreans generally support the principle of health maximization, they also believe that priority should be given to diseases that previously did not have any treatments. However, no priority was given to cancer or rare diseases.
本研究探讨了韩国人在有限的医疗资源分配中是否将疾病类型、罕见程度和替代治疗方法的可及性视为优先标准。
采用基于网络的调查方式,对 3482 名韩国成年人进行了代表性抽样调查。参与者被分为六个队列,根据比较的疾病、治疗的成本和收益而有所不同。每个队列都被问到两个问题:1)在所有其他条件相等的情况下,如何将固定预算分配到两组(癌症与非癌症、罕见与常见、无其他治疗方法与有几种治疗方法);2)当两组条件不同时的分配选择。采用 McNemar 检验评估两个问题之间的回答变化。
在对照条件下,大多数人选择治疗癌症和非癌症患者的人数相等,并倾向于治疗常见疾病和无替代治疗方法的疾病。然而,当两个比较组的治疗效果或成本发生变化时,选择倾向于更有效或成本更低的治疗方法。
尽管韩国人普遍支持健康最大化原则,但他们也认为应优先考虑以前没有任何治疗方法的疾病。然而,癌症或罕见疾病并没有得到优先考虑。